We examined the potential benefit of gene therapy in a mouse model of tuberous sclerosis complex (TSC) in which there is embryonic loss of Tsc1 (hamartin) in brain neurons. An adeno-associated virus (AAV) vector (serotype rh8) expressing a tagged form of hamartin was injected into the cerebral ventricles of newborn pups with the genotype Tsc1 cc (homozygous for a conditional floxed Tsc1 allele) SynI-cre + , in which Tsc1 is lost selectively in neurons starting at embryonic day 12. Vector-treated Tsc1 cc SynIcre + mice showed a marked improvement in survival from a mean of 22 days in non-injected mice to 52 days in AAV hamartin vectorinjected mice, with improved weight gain and motor behavior in the latter. Pathologic studies showed normalization of neuron size and a decrease in markers of mTOR activation in treated as compared to untreated mutant littermates. Hence, we show that gene replacement in the brain is an effective therapeutic approach in this mouse model of TSC1. Our strategy for gene therapy has the advantages that therapy can be achieved from a single application, as compared to repeated treatment with drugs, and that AAV vectors have been found to have minimal to no toxicity in clinical trials for other neurologic conditions. Although there are many additional issues to be addressed, our studies support gene therapy as a useful approach in TSC patients.
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Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disease caused by mutations in TSC1 or TSC2, genes which encode hamartin and tuberin, respectively (Crino, 2013; Kwiatkowski et al., 2010) . These proteins are critical in modulating the activity of mTOR which, in turn, regulates development and growth of many tissues (Laplante and Sabatini, 2012) . Benign tumors develop in the heart, brain, kidneys, skin, and lungs in TSC patients, and typically follow the classic Knudsen model in which there is a subsequent mutation in the corresponding normal allele ('second hit') occurring in somatic cells resulting in complete loss of either TSC1 or TSC2 expression in cells throughout the body. Neurologic symptoms are seen in over 90% of TSC patients, and include epilepsy, autism spectrum disorders, intellectual disability, attention deficit-hyperactivity, anxiety and sleep disorders (Jülich and Sahin, 2014) . Central nervous system (CNS) pathology in TSC includes cortical tubers (focal cortical lesions with giant cells), disorganized architecture with loss of layers in cortical migration tracts, enlarged neurons, reduced myelination and impaired neuronal connectivity (Crino,
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Abbreviations: AAV, adeno-associated virus; CBA, chicken beta actin; CMV, cytomegalovirus; CNS, central nervous system; CSF, cerebralspinal fluid; g.c., genome copies; GFAP, glial fibrillary acidic protein; HA-S6K, HA-S6 kinase; H&E, hematoxylin and eosin; HEK, human embryonic kidney; HA, human influenza hemagglutinin; HRP, horseradish peroxide; IHC, immunohistochemistry; IP, immunoprecipitation; i.v., intravenous; IV, intravascular; ICV, intracerebral ventricular; Neu N, neuronal nuclei; pS6, phospho-S6; RIPA, radio immunoprecipitation assay; SEGAs, subependymal giant cell astrocytomas; SMN, spinal motor atrophy; TSC, tuberous sclerosis complex. 
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